793 Darby Paoli Road
81 articles about Oncoceutics
Oncoceutics Invited to Present ONC201 at Public Advisory Committee Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019
Oncoceutics announced that the US Food and Drug Administration invited the company to present information regarding its lead compound ONC201 at the public advisory committee meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee on June 20, 2019.
In AML, ClpP is over-expressed in patient samples and its hyperactivation selectively kills cancer cells independent of p53 status, while not affecting normal cells.
Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,266,533 entitled “7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO [3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY” with an expiration date of January 29, 2036.
ABC2 Awards Grant to Develop Natural Disease History Benchmark for the Development of ONC201 in Midline Gliomas
Oncoceutics announced today that Accelerate Brain Cancer Cure (ABC2) has awarded a $116,523 grant to a research team at University of California, Los Angeles to perform a natural disease history study of adult midline gliomas, a certain type of aggressive brain tumors.
Oncoceutics announced today the publication of an article entitled "First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report” in the Journal of Neurosurgery (authored by Matthew D. Hall, M.D., MBA).
Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034.
Oncoceutics, Inc., announces the expansion of its diverse collaborations across the National Institutes of Health (NIH) involving its imipridone family of anti-cancer compounds
xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas
xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201.
In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.
Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a Histone 3 K27M (H3 K27M) mutation
Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology.
Oncoceutics and Calvert Research, LLC announced that the two companies have entered into a second product development and investment partnership agreement, this time to further develop and enable the submission of an IND application for ONC206, Oncoceutics' next generation molecule.
Oncoceutics announced the appointment of Minesh Mehta, MD, FASTRO, to the company’s Board of Directors.
Oncoceutics announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation.
Oncoceutics and Frontida BioPharm announced that the two companies have entered into a product development and commercialization agreement to further develop and scale-up the finished product manufacturing process for ONC201,
Oncoceutics announced that the Japanese Patent Office has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers, and glioblastoma.
Oncoceutics announced that the USPTO issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics' lead compound ONC201.
Oncoceutics today announced that five clinical and preclinical presentations on ONC201 and ONC206 for the treatment of high grade gliomas will be presented at the 22nd Annual Scientific Meeting and Education Day of the Society of Neuro-Oncology, held November 16th-19th in San Francisco.
Oncoceutics announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent high-grade gliomas that contain a specific mutation called the histone H3 K27M mutation.